Peptides

BPC-157

By Cameron McClevePublished Sep 27, 2026Updated Sep 28, 20264 min read

What is it?

BPC-157 is a synthetic peptide made of 15 amino acids and based on a sequence described in gastric research. It attracts interest for tendon and joint recovery and for gut problems. It is different from an ordinary dietary supplement: there is no FDA-approved BPC-157 medicine. [1,5]

How might it work?

In cell and animal studies, BPC-157 appears to affect blood-vessel formation, inflammation, and the activity of cells involved in tissue repair. Those findings make the recovery idea worth studying, but they do not establish exactly what BPC-157 does in a person or whether it speeds human healing. [1,2]

Why do people talk about it for recovery?

In a controlled rat experiment, surgically cut Achilles tendons treated with BPC-157 recovered better than saline-treated tendons on movement, tissue appearance, and mechanical-strength tests over 14 days. A broader review found many encouraging animal results for tendon, ligament, muscle, and bone injuries, but almost no comparable human testing. [1,2]

One human report followed people who had received a BPC-157 knee injection for different kinds of knee pain. Of 12 reached who received BPC-157 alone, 11 reported less pain; seven reported relief lasting more than six months. It was a retrospective report without a placebo group, standardized function testing, or scans showing tissue repair. It is an interesting pain report, not proof that an injured human tendon or ligament healed faster. [1,3]

A voluntary 2026 survey collected responses from 613 BPC-157 users; about 82% of those who described an outcome reported improvement. Those experiences are worth taking seriously. Because respondents chose to participate and the survey had no comparison group or verified products, it cannot measure how much of the improvement BPC-157 itself caused. [10]

What about gut health?

The gut connection began with animal studies. For example, BPC-157 reduced several experimentally induced stomach lesions in rats. Whether those effects carry over to common digestive symptoms in people is unknown. [4]

There was also a randomized, double-blind trial in 53 people with ulcerative colitis. It tested a BPC-157 enema against placebo for two weeks. Both groups improved; the reported difference between groups was uncertain enough to include no effect. Only a meeting abstract is available, so details of the outcome and analysis cannot be checked fully. This does not establish BPC-157 as an ulcerative-colitis treatment, and an enema study cannot establish the effect of an oral capsule or an injection. [5]

What should you know before considering it?

The FDA has not approved BPC-157 as a medicine. Its 2026 review raised concerns about product identity and purity, possible immune reactions to some formulations, and the small amount of human safety data. BPC-157 is also on the World Anti-Doping Agency's prohibited list for athletes subject to those rules. [5]

COMMON PRACTICE RANGE

How much?

250–500

FORM & SCHEDULE

What it refers to

mcg of BPC-157 per day by injection for recovery

These amounts describe common practice, not a dose established by human healing trials. BPC-157 is not FDA-approved; product quality and immune reactions are concerns. It is prohibited for athletes under WADA rules.

250–500 mcg — BPC-157 per day by subcutaneous injection for injury recovery is the range commonly discussed by peptide educators Jay Campbell and Hunter Williams. In the voluntary user survey, 500 mcg was the median per administration among 371 people who supplied a usable amount. These are practice patterns, not a range established by human dose-finding trials. [6,7,10]

Read detailed dosing notes

500–1,000 mcg per day orally is the range they discuss for gut-focused use. Campbell also describes 500–1,000 mcg per day by injection for acute injuries. Ben Greenfield's older, broader injury protocol totals 400–1,500 mcg per day; it should not be mistaken for the most common range. [6–8]

Alex Kikel emphasizes how much the target injury and person can change a protocol, so one universal dose would be misleading. These educator-reported amounts have not been established as effective or safe for recovery or gut treatment in human dose-finding studies. The knee injection and ulcerative-colitis enema studies cannot validate the injected or oral ranges above. [3,5,9]

For a persistent injury or gut symptoms, a clinician can help identify the cause and discuss treatments supported by human evidence. BPC-157 should not delay diagnosis, rehabilitation, or prescribed care. Product quality and possible immune reactions remain concerns. [5]

Sources & further reading